NCT06379867Recruiting
A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
Haisco Pharmaceutical Group Co., Ltd.Phase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Anesthesia
- Drug/Device/Intervention
- HSK3486
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Apr 07, 2024
- End date
- Aug 30, 2024
- Enrollment
- 48 participants
Primary outcome
ΔQTcI
Summary
Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for
 healthy subjects.
ICD-10 classifications
Anaesthetic, unspecifiedOther and unspecified general anaestheticsLocal anaestheticsOther complications of anaesthesiaComplication of anaesthesia during labour and delivery, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06379867
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06379867 through Pure Global AI's free database. This Phase 1 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Anesthesia. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.